# ScoreItem: DHEA-S - Mulheres (50-59 anos)

**ID:** `c77cedd3-2800-76d4-90ca-12bef80585a3`
**FullName:** DHEA-S - Mulheres (50-59 anos) (Exames - Laboratoriais)
**Unit:** ¬µg/dL
**Gender:** female
**Age Min:** 50 anos
**Age Max:** 59 anos

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 7 artigos
- Avg Similarity: 0.686

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-76d4-90ca-12bef80585a3`.**

```json
{
  "score_item_id": "c77cedd3-2800-76d4-90ca-12bef80585a3",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** DHEA-S - Mulheres (50-59 anos) (Exames - Laboratoriais)
**Unidade:** ¬µg/dL
**G√™nero:** female
**Faixa Et√°ria:** 50-59 anos

**30 chunks de 7 artigos (avg similarity: 0.686)**

### Chunk 1/30
**Article:** Ritmo Circadiano Eixo HPA - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.739

omens, a dose m√©dia de DHEA varia entre 25 e 50 miligramas.
- Notavelmente, uma dose de 50 mg de DHEA, geralmente associada a homens, tamb√©m √© indicada para mulheres com o objetivo de melhorar o humor, o bem-estar e a fun√ß√£o sexual.
**A S√≠ndrome da Fadiga Cr√¥nica (SFC) afeta predominantemente adultos jovens entre 20 e 40 anos, com uma preval√™ncia duas a tr√™s vezes maior em mulheres do que em homens.**
- A SFC √© mais comum em adultos na faixa et√°ria de 20 a 40 anos.
- As mulheres s√£o diagnosticadas com SFC de duas a tr√™s vezes mais frequentemente do que os homens, indicando uma clara disparidade de g√™nero na preval√™ncia da condi√ß√£o.
### Achados Adicionais Chave
- A ideia de que as gl√¢ndulas adrenais s√£o as primeiras a mostrar sinais de cansa√ßo foi introduzida em uma publica√ß√£o de 1921.

---

### Chunk 2/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.731

Stanczyk FZ, Bairey Merz CN. DHEA-S levels and
cardiovascular disease mortality in postmenopausal women: Results from the National
Institutes of Health‚ÄìNational Heart, Lung, and Blood Institute (NHLBI)-sponsored Women‚Äôs
Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985‚Äì4992
204. Christiansen JJ, Andersen NH, S√∏rensen KE, Pedersen EM, Bennett P, Andersen M,
Christiansen JS, J√∏rgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in
female adrenal failure: no impact on endothelial function and cardiovascular parameters
despite normalization of androgen status. Clin Endocrinol 2007;66:426‚Äì433
205. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of
oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240‚Äì245
206. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193‚Äì204
207.

---

### Chunk 3/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.717

dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione,
superimposed on growth hormone substitution, on quality of life and insulin-like growth factor
I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-
over trial. J Clin Endocrinol Metab 2005;90:3295‚Äì303
145. Lovas K, Gebre-Medhin G, Trovik T, et al. Replacement of dehydroepiandrosterone in
adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized
parallel group clinical trial. J Clin Endocrinol Metab 2003;88:1112‚Äì8
146. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning
as women transition through menopause: results from the Study of Women‚Äôs Health Across
the Nation. Menopause 2009;16:442‚Äì52
147.

---

### Chunk 4/30
**Article:** Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women (2025)
**Journal:** Clinical Endocrinology
**Section:** abstract | **Similarity:** 0.714

Diretriz cl√≠nica da Society for Endocrinology para avalia√ß√£o de excesso androg√™nico em mulheres. DHEA-S s√©rico √© a medida mais confi√°vel de produ√ß√£o adrenal de andr√≥genos, particularmente √∫til na transi√ß√£o perimenop√°usica. Aproximadamente 25% da produ√ß√£o androg√™nica ocorre nas adrenais em mulheres pr√©-menop√°usicas, aumentando para 100% na p√≥s-menopausa. Decl√≠nio de DHEA-S inicia aos 30 anos devido √† involu√ß√£o da zona reticular adrenal.

---

### Chunk 5/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.714

208
]. In humans studies, however, the results  are
rather inconsistent. In some studies, the lower levels of DHEA seen with aging have been
associated with impaired glucose tolerance, insulin resistance and diabetes [
212
-
215
], while
in another [
216
] exactly the opposite relation was shown as higher levels of DHEA were
13

associated with impaired glucose tolerance and diabetes mellitus in post-menopausal
women. The truth regarding DHEA/DHEAS and insulin resistance and its associated
conditions gets even more complicated considering conflicting results from interventional
studies with DHEA replacement. Thus, an ameliorating effect of long-term treatment with
DHEA on insulin resistance was described in a group of middle-aged hypo-adrenal women
treated with DHEA [
217
], but also in groups of elderly men [
97
] and postmenopausal women
[
97,217-220
] replaced with DHEA.

---

### Chunk 6/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.713

was further supported by the results of Egger¬ís regression test.Discussionis meta-analysis of randomized controlled trials (RCTs) evaluated the eÔ¨Äects of dehydroepiandrosterone (DHEA) supplementation on testosterone and estradiol levels in postmenopausal women. Our analysis of 21 RCTs revealed that DHEA supplementation signiÔ¨Åcantly increased both testosterone and estradiol concentrations, although substantial heterogeneity was observed across the included trials.Our Ô¨Åndings indicate that DHEA is particularly eÔ¨Äec-tive in elevating testosterone levels when administered at dosages  50 mg/day. Additionally, a marked increase in estradiol levels was noted among participants aged  60 years receiving the same dosage. ese Ô¨Åndings 
Fig. 2 Forest plot of the randomized controlled trials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig.

---

### Chunk 7/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.711

levels [
160
], making the relation between
DHEA/DHEAS and depression even more confusing.
Several interventional studies have shown that DHEA replacement may improve negative
and depressive symptoms [
134
,
135
,
161
-
163
]
. 
In women with adrenal insufficiency, in
11

particular, oral DHEA replacement significantly improved the overall well-being, as well as
scores for depression and anxiety [
108
]; similar results were found in the management of the
negative symptoms of schizophrenia
 [
163
]. 
Most recent placebo-controlled randomized
trials, however, failed to demonstrate a beneficial effect of DHEA therapy on mood, quality of
life, perceptions of physical and emotional health, and life satisfaction in postmenopausal
women [
73
,
75
,
76
]. Thus the therapeutic role of DHEA on mood disorders remains unclear.
3d.

---

### Chunk 8/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.704

reavaliar a cada 6‚Äì8 semanas, checar SHBG, estradiol, DHT se pertinente) para padronizar seguimento.
### 8. DHEA (prasterona): papel, prescri√ß√£o e diferen√ßas entre sexos
- DHEA/DHEA-S: pr√≥-horm√¥nio, n√£o considerado horm√¥nio pleno; decl√≠nio com a idade, especialmente adrenal.
- Em mulheres, pode estimular horm√¥nios subsequentes; em homens, n√£o costuma ter fun√ß√£o robusta para estimular outros horm√¥nios.
- No Brasil, prescri√ß√£o como prasterona; estudos principalmente com comprimido; creme seria mais fisiol√≥gico, por√©m menos estudado; ambas formas poss√≠veis.
- Doses mulheres: baixas (10‚Äì15 mg) e monitorar porque pode elevar horm√¥nios indesejados; utilidade em infertilidade/autoimunes com dose b√°sica.
- Conceito de ‚Äúdesgaste‚Äù glandular ao longo da vida aplic√°vel √†s adrenais.
> **Sugest√µes de IA**
> - Organiza√ß√£o: Voc√™ delimitou bem diferen√ßas por sexo; inclua crit√©rios claros de quando considerar prasterona (indica√ß√µes vs quando evitar).

---

### Chunk 9/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.700

ffect of Dehydroepiandrosterone
on Muscle Strength and Physical Function in Older Adults: A Systematic Review. J Am
Geriatr Soc 2011;59:997‚Äì1002
75. Kritz-Silverstein D, von M√ºhlen D, Gail A. Laughlin GA, Bettencourt R. Effects of
dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA
and well-ness (DAWN) trial. J Am Geriat Soc 2008;56:1292‚Äì8
76. Panjari M, Bell RJ, Jane F, et al..A randomized trial of oral DHEA treatment for sexual
function, well-being, and menopausal symptoms in postmenopausal women with low libido. J
Sex Med 2009; 6: 2579‚Äì2590
77. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and metaanalysis of
randomized placebo-controlled trials of DHEA treatment effects on quality of life in women
with adrenal insufficiency.
J Clin Endocrinol Metab 2009;94:3676‚Äì81
78. Labrie F, Archer D, Bouchard C, et al.

---

### Chunk 10/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.698

80 anos com testosterona de 500-600, sugerindo que seus n√≠veis de pico na juventude poderiam ter sido muito mais altos (ex: 1.500).
*   **Decl√≠nio Hormonal Feminino e DHEA**
    - Mulheres tamb√©m experimentam um decl√≠nio na testosterona, que √© produzida pelos ov√°rios e adrenais. A queda pode ser menos linear que nos homens, pois a produ√ß√£o adrenal pode ser preservada.
    - O DHEA (deidroepiandrosterona), um pr√≥-horm√¥nio precursor, diminui nitidamente com a idade, indicando um "desgaste" da gl√¢ndula adrenal.
    - A prescri√ß√£o de DHEA (prasterona no Brasil) √© feita em comprimidos (forma mais estudada) ou creme (forma mais fisiol√≥gica). Doses para mulheres s√£o menores (10-15mg) para evitar convers√µes indesejadas. Para homens, sua fun√ß√£o como estimulador de outros horm√¥nios √© menos estabelecida.
### 4.

---

### Chunk 11/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.693

asures [
27]
.
Since DHEA is the main source of androgens in women, its age-related decline leads to a
corresponding decrease in the total androgen pool. Although there is actually no defined
level of androgen below which women can be said to be deficient, the decline of DHEA in
postmenopausal women would 
suggest
 they are ‚Äúdeficient‚Äù in both estrogens and androgens
[16]. The declining circulating levels of adrenal androgens with advancing age have been
related to clinical symptoms and disorders (see below).
In the last few years, the concept that adrenal androgen production gradually declines with
advancing age has changed following the analysis of the longitudinal data collected in the
Study of Women‚Äôs Health Across the Nation (SWAN) [28].

---

### Chunk 12/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.693

late postmenopause. Gynecolog Endocrinol 2000;14:342‚Äì363
139. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function andwellbeing.
Human Reprod Update 2007;13:239‚Äì48 
140. Arlt W, Callies F, van Vlijmen JC, et al.. Dehydroepiandrosterone replacement in
women with adrenal insufficiency. N Engl J Med 1999; 341: 1013‚Äì1020
141. Mortola JF, Yen SS.The effects of oral dehydroepiandrosterone on endocrine-metabolic
parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71: 696‚Äì704
142. Wolf OT, Neumann O, Hellhammer DH, et al..Effects of a two-week physiological
dehydroepiandrosterone substitution on cognitive performance and well-being in healthy
elderly women and men. J Clin Endocrinol Metab 1997; 82: 2363‚Äì2367
143. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144.

---

### Chunk 13/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.686

n in the analysis. However, the potential inÔ¨Çuence of such metabolic factors on DHEA supplementation outcomes could introduce bias. Despite this, sensitivity analyses indicated that no single study disproportionately aÔ¨Äected the overall results, supporting the robustness of our conclusions.Our review did not account for these metabolic and comorbidity-related factors, which future research should control for or report in detail to minimize bias. Additionally, sensitivity analyses addressing these vari-ables would be valuable in future meta-analyses.Conclusionis meta-analysis found that DHEA supplementation at doses of 50 mg/day or higher signiÔ¨Åcantly increased testosterone levels, and in participants aged 60 years or older, signiÔ¨Åcantly elevated estradiol levels.

---

### Chunk 14/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.683

ement
in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin
sensitivity and lipid metabolism. Aging Male 2003; 6:151‚Äì156
27

108. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio
B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on
body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol
Metab 2001;86:1968‚Äì 1972
109. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G.
Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab
1999;84:1527‚Äì1533
110. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau
M, Marini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-
year-old individuals on muscle function and cross-sectional area: A double-blind placebo-
controlled trial. Arch Int Med 2003;163:720‚Äì727
111.

---

### Chunk 15/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XVII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.675

do ao bloqueio da enzima 5-alfa-redutase.
    *   16-hidroxiestrona e 4-hidroxiestrona: Elevadas, indicando desvio do metabolismo hormonal.
    *   Beta-pregnanediol e Alfa-pregnanediol: N√≠veis baixos, indicando deple√ß√£o e estresse.
*   **Exames de Sangue Anteriores:** A testosterona s√©rica estava em um n√≠vel normal-baixo.
**Achados Gerais e de Estudos (Apresenta√ß√£o M√©dica):**
*   **Minoxidil:** Eficaz em cerca de 33% dos casos para queda de cabelo. A efic√°cia depende do gene SULT1A1; um polimorfismo comum neste gene leva √† falta de resposta.
*   **Finasterida e Dutasterida:**
    *   **Mecanismo:** Inibem a enzima 5-alfa-redutase, que converte testosterona em DHT. A dutasterida √© mais potente, inibindo os tipos 1 e 2 da enzima.
    *   **S√≠ndrome P√≥s-Finasterida:** Associa√ß√£o de sintomas sexuais, f√≠sicos e psicol√≥gicos que se desenvolvem durante ou ap√≥s o uso e persistem ap√≥s a descontinua√ß√£o.

---

### Chunk 16/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.674

].
Given that a) the adrenal steroids are the most abundant sex steroids in post-menopausal
women and provide a large reservoir of precursors for the intracellular production of
androgens and estrogens in non-reproductive tissues, b) DHEA levels decline with age, c)
pre- and post-menopausal women with lower sexual responsiveness have lower levels of
serum DHEAS [
132
] and d) treatment of postmenopausal women with estrogen and
testosterone have shown some improvement in sexual function, it was proposed that
restoring the circulating levels of DHEA to those found in young women may improve sexual
function and well-being in postmenopausal women [
81
]. Some early 
randomized trials
 that
suffered from methodological issues, such as small number of participants, short treatment
duration and supraphysiological doses, demonstrated positive effects of DHEA replacement
on sexual function and well-being [
70
,
133
-
136
], as well as on relief of menopausal
symptoms [
136
,
138
].

---

### Chunk 17/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** other | **Similarity:** 0.673

verted into its sulfated form, DHEA sulfate (DHEA-S), which circulates at much higher concentrations and can be further metabolized into active sex hormones as needed [5].DHEA levels decline signiÔ¨Åcantly with age, decreasing by approximately 70% between the ages of 20 and 60, pri-marily due to reduced adrenal production. DHEA sup-plementation has been explored as an adjunct therapy for postmenopausal women, alongside hormone replace-ment therapy (HRT), and has demonstrated potential beneÔ¨Åts in improving metabolic and endocrine function, as well as sexual health [6]. DHEA exerts androgenic, estrogenic, and steroidal eÔ¨Äects and has been associated with various biological functions, including antioxidant properties, neuroprotection, and anticancer activity [7].

---

### Chunk 18/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.671

randomized clinical trials. Exp Gerontol. 2020;141: 111110. 41. Zhu Y, Qiu L, Jiang F, GƒÉman M-A, Abudoraehem OS, Okunade KS, et al. The eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on estradiol levels in women: a dose-response and meta-analysis of randomized clinical trials. Steroids. 2021;173:108889. 42. Jamka K, Adamczuk P, Skowronska A, Bojar I, Raszewski G. Assess-ment of the eÔ¨Äect of estradiol on biochemical bone turnover markers among postmenopausal women. Ann Agric Environ Med. 2021;28(2):78¬ñ96. 43. Clark BJ, Prough RA, Klinge CM. Mechanisms of action of dehydroepi-androsterone. Vitam Horm. 2018;108:29¬ñ73. 44. Brzozowska M, Lewi≈Ñski A. Changes of androgens levels in meno-pausal women. Menopause Review/PrzeglƒÖd Menopauzalny. 2020;19(4):151¬ñ4. 45. Nair KS, Rizza RA, O¬íBrien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647¬ñ59. 46. Villareal DT, Holloszy JO.

---

### Chunk 19/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.671

o DHEA supplementation.Biochemically, DHEA serves as a precursor to both estrogens and androgens. Once converted to DHEA sulfate in the liver, it undergoes further enzymatic trans-formation in peripheral tissues, where it contributes to the synthesis of active estrogens and androgens, includ-ing estradiol and testosterone [6].It is important to note that elevated levels of estradiol can have adverse eÔ¨Äects, such as stimulating the endo-metrium [27]. Consequently, prolonged high estradiol levels may increase the risk of developing endometrial carcinoma [49]. erefore, it is crucial to use low doses of DHEA to raise estradiol levels without overstimulating the endometrium [50]. In our review, subgroup analysis based on DHEA dosage showed that doses of 50 mg/day or higher signiÔ¨Åcantly increased estradiol levels.

---

### Chunk 20/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.671

upraphysiological doses, demonstrated positive effects of DHEA replacement
on sexual function and well-being [
70
,
133
-
136
], as well as on relief of menopausal
symptoms [
136
,
138
]. Similarly, women with adrenal insufficiency treated with oral DHEA
replacement demonstrated significant improvement in overall well-being, as well as in
frequency of sexual thoughts, sexual interest, and satisfaction [
139, 140
]. Other studies,
however, failed to show any benefit of DHEA replacement on sexual function, well-being and
10

menopausal symptoms in peri- and post-menopausal women [
75
,
76
,
105,141
,
142
] and
women with adrenal insufficiency [
143
-
145
]. A recent review of the available data concluded
that current evidence does not support the routine use of DHEA in women with adrenal
insufficiency [
77
].

---

### Chunk 21/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.671

Windahl SH, Wu J, et al. Dehydroepiandrosterone supplementation results in varying tissue-speciÔ¨Åc levels of dihydrotestosterone in male mice. Endocrinology. 2022;163(12):163. 12. Jankowski CM, Wolfe P, Schmiege SJ, Nair KS, Khosla S, Jensen M, et al. Sex-speciÔ¨Åc eÔ¨Äects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: a pooled analysis of four clinical trials. Clin Endocrinol. 2019;90(2):293¬ñ300.

Page 12 of 13Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
 13. Yuan H, Ou Q, Ma Y, Chen R, Wu H, Li F, et al. EÔ¨Éciency of DHEA on diminished ovarian reserve patients undergoing IVF-ET based on ultrasonography. Int J Clin Exp Med. 2016;9:14337¬ñ44. 14. ScheÔ¨Äers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehy-droepiandrosterone for women in the perior postmenopausal phase. Cochrane Datab Syst Rev. 2015(1). 15. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM.

---

### Chunk 22/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.669

Clin Endocrinol Metab 2009;94:3676‚Äì81
78. Labrie F, Archer D, Bouchard C, et al. 
Effect of intravaginal dehydroepiandrosterone
(Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause (New
York, NY) 2009;16:923‚Äì31
25

79. 
van den Brandt PA
,
 
Spiegelman D
,
 
Yaun SS
,
 
Adami HO
,
 
Beeson L
,
 
Folsom AR
,
 
Fraser
G
,
 
Goldbohm RA
,
Graham S
,
 
Kushi L
,
 
Marshall JR
,
 
Miller AB
,
 
Rohan T
,
 
Smith-Warner
SA
,
 
Speizer FE
,
 
Willett WC
,
 
Wolk A
,
Hunter DJ
. Pooled analysis of prospective cohort
studies on height, weight, and breast cancer risk. 
Am J Epidemiol.
 
2000 ;152:514-27.
80. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin
Endocrinol Metab 2009;94:1059‚Äì1067
81. Panjari M, Davis SR. DHEA for postmenopausal women: A review of the evidence.
Maturitas 2010;66:172‚Äì179
82.  Labrie F, Belanger A, Belanger P, et al. Metabolism of DHEA in postmenopausal
women following percutaneous administration.

---

### Chunk 23/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.666

y oÔ¨Äer estro-genic beneÔ¨Åts, such as improved bone health and pro-tection against bone loss [47]. ese results are further supported by other meta-analyses that reported similar hormonal increases following DHEA supplementation [40, 41].Our review also observed a signiÔ¨Åcant increase in tes-tosterone levels with DHEA supplementation admin-istered for  26 weeks. In line with this, the review conducted by Wierman etal. evaluated the eÔ¨Äect of DHEA over a long period in older women and found that both estradiol and testosterone levels signiÔ¨Åcantly increased [48]. A prospective clinical trial found that 50 mg/day of DHEA led to a higher estradiol concentra-tion and testosterone levels after 6 months of treatment. ese Ô¨Åndings highlight the dynamic, time-dependent hormonal response to DHEA supplementation.Biochemically, DHEA serves as a precursor to both estrogens and androgens.

---

### Chunk 24/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.665

rett-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of
dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed
mood in older women: The Rancho Bernardo Study. J Am Geriatr Soc 1999;47:685‚Äì691
156. Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone
levels in major depression in adults. Biol Psychiatry 2000;48:989‚Äì995
157. Morrison MF, Freeman EW, Lin H, and Sammel MD. Higher DHEA-S
(Dehydroepiandrosterone Sulfate) Levels are Associated with Depressive Symptoms during
the Menopausal Transition: Results from the PENN Ovarian Aging Study. Arch Womens
Ment Health  2011; 14: 375‚Äì382
158. Takebayashi M, Kagaya A, Uchitomi Y, Kugaya A, Muraoka M, Yokota N, Horiguchi J,
Yamawaki S. Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short
communication.J Neural Transm  1998; 105:537-42
159. Assies J, Visser I, Nicolson NA, Eggelte TA, Wekking EM, Huyser J, Lieverse R,
Schene AH.

---

### Chunk 25/30
**Article:** Ritmo Circadiano Eixo HPA - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.665

mente.
    - No Brasil, prescreve-se prasterona.
    - Doses m√©dias: 10‚Äì15 mg para mulheres e 25‚Äì50 mg para homens.
    - Em homens, DHEA n√£o se mostrou eficaz para aumentar horm√¥nios esteroides como precursor.
    - Avalia√ß√£o laboratorial pelo S-DHEA (sulfato de DHEA), forma de reserva no sangue.
### 3. S√≠ndrome da Fadiga Cr√¥nica (SFC)
*   **Defini√ß√£o e Sintomas**
    - Fadiga intensa, de causa desconhecida, persistente, limitante e que n√£o melhora com descanso.
    - Frequentemente confundida com depress√£o, astenia (melhora com sono) e fraqueza (perda de for√ßa muscular).
    - Sintomas associados: dores articulares e musculares, cefaleia, ansiedade, sintomas depressivos, dist√∫rbios cognitivos e do sono, intoler√¢ncia a exerc√≠cios.
    - Classifica√ß√£o por tempo: recente (<1 m√™s), prolongada (>1 m√™s), cr√¥nica (>6 meses).
*   **Diagn√≥stico e Etiologia**
    - Dificuldade diagn√≥stica por desconhecimento etiol√≥gico e quantifica√ß√£o dos sintomas.

---

### Chunk 26/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.664

ials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig. 3 Forest plot of the randomized controlled trials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum testosterone concentrations
Fig. 4 Funnel plot of the weighted mean diÔ¨Äerence (WMD) versus the standard error (s.e.) of the WMD

Page 10 of 13Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
are consistent with a previous meta-analysis by Li etal., which reported increased testosterone levels in partici-pants receiving > 50 mg/day of DHEA for  12 weeks, particularly among those under 60 years of age [40]. Sim-ilarly, Zhu etal. found that estradiol concentrations were signiÔ¨Åcantly increased in participants aged  60 years who received  50 mg/day of DHEA for  26 weeks [41].

---

### Chunk 27/30
**Article:** Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women (2021)
**Journal:** BMC Geriatrics
**Section:** results | **Similarity:** 0.663

andgaitspeed.Furtherresultsshowedthatpostmeno-pausalwomenwithsarcopeniaweremorelikelytohavehigherDHEAlevels.However,T2andE2werenotre-latedtomusclemass,gripstrengthorgaitspeed.TheseresultssuggestedthatthecirculatingsexhormonesDHEAwasabetterbiomarkerthanT2andE2formusclestrengthandgaitspeed,whichlikelyoccurredbecauseDHEAisaprecursorforsexsteroids.Threerea-sonsmaysupportthishypothesis.First,DHEAdoesnotbindtosexhormone-bindingglobulin(SHBG),whichsuggeststhatDHEAhasfreeaccesstotargetorganscomparedtoSHBG-boundE2andT2[24].Second,DHEAisanandrogenprehormoneproducedinthezonareticularisofthefemaleadrenalglandandovarianthecacells,anditactsasanupstreamprecursorofT2andE2inpostmenopausalwomen[25].DHEAinpostmeno-pausalwomenbecomesthepredominantsexhormoneinsteadofE2[26].CirculatingDHEAprovidessubstratesthatarerequiredforconversionintopotentandrogensandestrogensinperipheraltissues.SkeletalmusclesarecapableofsynthesizingandrogensandestrogensfromDHEA[27].Therefore,TandE2levelsinserumdonotrepresenttheconcen

---

### Chunk 28/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.663

/ doi. org/ 10. 1046/j. 1365- 2265. 1998. 00507.x. 38. Kudielka BM, Hellhammer J, Hellhammer DH, Wolf OT, Pirke KM, Varadi E, et al. Sex diÔ¨Äerences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998;83(5):1756¬ñ61. https:// doi. org/ 10. 1210/ jcem. 83.5. 4758. 39. Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abra-ham GE, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995;63(5):1027¬ñ31. 40. Li Y, Ren J, Li N, Liu J, Tan SC, Low TY, et al. A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials. Exp Gerontol. 2020;141: 111110. 41. Zhu Y, Qiu L, Jiang F, GƒÉman M-A, Abudoraehem OS, Okunade KS, et al.

---

### Chunk 29/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.661

oups of elderly men [
97
] and postmenopausal women
[
97,217-220
] replaced with DHEA. The DHEA dose used ranged between 25 and 100
mg/day 
per os
 and the duration of treatment varied between 3 and 12 months; in one study
transdermal DHEA was used [
220
]. Most other interventional studies addressing this issue,
failed to demonstrate any significant effect of DHEA on insulin resistance/sensitivity
[
73
,
94
,
105
,
108
,
111
,
112
,
143
,
205
,
221
-
224
] and so did 
a
 recent review of the available data
regarding use of DHEA in women with adrenal insufficiency [
77
]. Remarkably
, 
Mortola and
Yen [
140
] reported worsening insulin resistance with DHEA replacement in
postmenopausal
 
women; in this study however, the number of participants was small (n=6),
the duration of treatment short (28 days), and the DHEA dosage supraphysiological (1600
mg/day 
per os
). Puting together the above, the relation between DHEA and carbohydrate
metabolism is still uncertain.
3g.

---

### Chunk 30/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.659

sely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol. 2000;75(2¬ñ3):159¬ñ66. 8. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, its sulfate and cognitive functions. Clin Pract Epidemiol Ment Health CP EMH. 2016;12:24. 9. Ma Y, Fan X, Han J, Cheng Y, Zhao J, Fang W, et al. Critical illness and sex hormones: response and impact of the hypothalamic¬ñpituitary¬ñgonadal axis. Therap Adv Endocrinol Metab. 2025;16:20420188251328190. 10. Kawakita T, Yasui T, Yoshida K, Matsui S, Iwasa T. Correlations of andros-tenediol with reproductive hormones and cortisol according to stages during the menopausal transition in Japanese women. J Steroid Biochem Mol Biol. 2021;214: 106009. 11. Colld√©n H, Nilsson ME, Norl√©n A-K, Landin A, Windahl SH, Wu J, et al. Dehydroepiandrosterone supplementation results in varying tissue-speciÔ¨Åc levels of dihydrotestosterone in male mice. Endocrinology. 2022;163(12):163. 12.

---

